Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

Edward S. Kim, MD
Published: Tuesday, Mar 20, 2018



Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

After findings from the PACIFIC trial were presented at the 2017 ESMO Congress many practices, such as Levine Cancer Institute, added durvalumab (Imfinzi) as a consolidation treatment after concurrent chemoradiation. Durvalumab, a PD-L1 inhibitor, improved median progression-free survival by 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P <.0001).

In February 2018, the FDA granted approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy. Durvalumab has become the new benchmark for stage III NSCLC, says Kim.


Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

After findings from the PACIFIC trial were presented at the 2017 ESMO Congress many practices, such as Levine Cancer Institute, added durvalumab (Imfinzi) as a consolidation treatment after concurrent chemoradiation. Durvalumab, a PD-L1 inhibitor, improved median progression-free survival by 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P <.0001).

In February 2018, the FDA granted approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy. Durvalumab has become the new benchmark for stage III NSCLC, says Kim.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x